Rainbow Pie: Unleashing the Power of CBG

It’s more than just THC. Our newest offering, Rainbow Pie, not only delights the taste buds but also boasts up to 2% cannabigerol (CBG). While THC often takes centre stage,  minor cannabinoid CBG is gaining prominence.

Research indicates that this non-intoxicating minor cannabinoid could be especially beneficial for individuals grappling with inflammatory issues. CBG's anti-inflammatory properties position it as a promising option for healthcare providers exploring alternatives or adjunct approaches to address conditions linked to inflammation, such as chronic pain, inflammatory bowel disease or arthritis.

CBG's capabilities extend beyond combating inflammation. Its neuroprotective properties make it a compelling candidate for supporting brain health in the context of neurodegenerative diseases. The potential molecular mechanisms underpinning cannabigerol's (CBG) neuroprotective effects are multifaceted. CBG's anti-inflammatory profile may assist in mitigating neuronal damage in various neurodegenerative conditions. Serving as an antioxidant, CBG combats free radicals, potentially alleviating oxidative stress and safeguarding neurons from degeneration.

Moreover, CBG's interaction with CB1 and CB2 receptors within the endocannabinoid system may impact neurotransmitter release, contributing to the regulation of neuronal function and potentially enhancing neuroprotection.


CBG may even help some patients boost their appetite. Research has found that CBG stimulates hunger without the intoxicating effects of THC. In a recent animal study, CBG increased overall food intake and how often test rats ate without causing negative side effects, such as impairing coordination or movement. This suggests that CBG could be a potential treatment for conditions like eating disorders or loss of appetite post-chemotherapy.